Results obtained on cognitive, behavioural, and functional variables at baseline and follow up visits in the subgroup of nine patients with an 18 month follow up
| 3 Months | 6 Months | 12 Months | 18 Months | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | SR | Baseline (mean (SD)) | Mean (SD) | % | p Value | Mean (SD) | % | p Value | Mean (SD) | % | p Value | Mean (SD) | % | p Value | |||
| Significant data are in bold face. %, percentage change v baseline. a: +, improvement; −, decline; lower score = worse performance. b: −, improvement; +, decline; lower score = better clinical condition. ADL-UPDRS, activities of daily living subscale of the unified Parkinson’s disease rating scale; MMSE, mini-mental state examination; MWCST, modified Wisconsin card sorting test; PDQL, Parkinson’s disease quality of life questionnaire; SR, score range. | |||||||||||||||||
| Raven progressive matrices ’47a | 0 to 36 | 26.2 (6.3) | 28.2 (6.2) | +7.6% | 0.0425 | 27.4 (7.0) | +4.2% | 0.1730 | 28.6 (6.5) | +9.2% | 0.0280 | 29.0 (6.7) | +10.2% | 0.0935 | |||
| Letter verbal fluencya | 32.6 (13.8) | 23.5 (7.6) | −27.9% | 0.0280 | 31.1 (12.7) | −4.6% | 0.4008 | 31.4 (11.9) | −3.7% | 0.7794 | 26.6 (12.6) | −18.4% | 0.0357 | ||||
| MWCST: total errorsb | 0 to 48 | 16.1 (14.0) | 11.1 (10.4) | −31.1% | 0.1730 | 8.4 (10.4) | −47.8% | 0.0464 | 7.7 (9.3) | −52.2% | 0.1730 | 6.3 (4.8) | −61.5% | 0.0759 | |||
| MWCST: perseverative errorsb | 0 to 48 | 8.3 (8.2) | 3.0 (4.3) | −63.4% | 0.0277 | 2.4 (3.6) | −70.7% | 0.0277 | 2.3 (5.2) | −72.3% | 0.0180 | 3.1 (3.4) | −62.2% | 0.0592 | |||
| Zung’s depression scaleb | 20 to 80 | 43.3 (5.5) | 31.7 (6.5) | −26.6% | 0.0280 | 33.4 (9.3) | −22.7% | 0.0425 | 32.6 (6.6) | −24.7% | 0.0180 | 33.6 (9.4) | −22.5% | 0.0630 | |||
| Zung’s anxiety scaleb | 20 to 80 | 36.7 (4.1) | 31.8 (4.2) | −13.4% | 0.0277 | 30.2 (4.4) | −17.7% | 0.0464 | 28.0 (5.2) | −23.7% | 0.0346 | 30.3 (6.4) | −17.7% | 0.0630 | |||
| ADL-UPDRS, off drug treatmentb | 0 to 52 | 33.1 (7.8) | 8.9 (5.8) | −73.2% | 0.0077 | 8.2 (5.7) | −75.2% | 0.0077 | 8.3 (5.0) | −74.8% | 0.0077 | 7.4 (4.4) | −77.5% | 0.0077 | |||
| ADL-UPDRS, on drug treatmentb | 0 to 52 | 12.4 (10.7) | 9.0 (5.5) | −27.7% | 0.7998 | 7.3 (5.7) | −41.1% | 0.0129 | 5.2 (4.4) | −58.0% | 0.0173 | 5.4 (4.5) | −56.3% | 0.0284 | |||
| PDQLb | 0 to 148 | 87.7 (17.1) | 37.6 (17.6) | −57.1% | 0.0180 | 35.6 (14.9) | −59.4% | 0.0180 | 39.6 (20.3) | −54.8% | 0.0180 | 49.7 (35.4) | −43.3% | 0.0425 | |||